These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 17187467)

  • 1. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of the Xience V® everolimus-eluting coronary stent system.
    Claessen BE; Caixeta A; Henriques JP; Piek JJ
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Buellesfeld L; Grube E
    Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
    Stone GW; Rizvi A; Sudhir K; Newman W; Applegate RJ; Cannon LA; Maddux JT; Cutlip DE; Simonton CA; Sood P; Kereiakes DJ;
    J Am Coll Cardiol; 2011 Jun; 58(1):19-25. PubMed ID: 21514084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
    Kandzari DE; Leon MB; Popma JJ; Fitzgerald PJ; O'Shaughnessy C; Ball MW; Turco M; Applegate RJ; Gurbel PA; Midei MG; Badre SS; Mauri L; Thompson KP; LeNarz LA; Kuntz RE;
    J Am Coll Cardiol; 2006 Dec; 48(12):2440-7. PubMed ID: 17174180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents.
    Chieffo A; Foglieni C; Nodari RL; Briguori C; Sangiorgi G; Latib A; Montorfano M; Airoldi F; Michev I; Carlino M; Colombo A; Maseri A
    Am J Cardiol; 2009 Dec; 104(12):1660-7. PubMed ID: 19962471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
    Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
    Silber S
    J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher).
    Biondi-Zoccai G; Lotrionte M; Moretti C; Agostoni P; Sillano D; Laudito A; Sheiban I
    Minerva Cardioangiol; 2008 Feb; 56(1):55-65. PubMed ID: 18432169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.